(S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H315：피부에 자극을 일으킴

  H319：눈에 심한 자극을 일으킴

  H335：호흡 자극성을 일으킬 수 있음

• 예방조치문구

  P280：보호장갑/보호의/보안경/안면보호구를 착용하시오.

  P304+P340：흡입하면 신선한 공기가 있는 곳으로 옮기고 호흡하기 쉬운 자세로 안정을 취하시오.

(S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER 화학적 특성, 용도, 생산

• 개요

  CHF-1301 was launched as an injection in Italy for the treatment of patients with Parkinson's disease, particularly those with complications in their clinical responses. CHF-1301 is the methyl ester of L-Dopa (levodopa), the immediate precursor of dopamine. Thus, this prodrug is more soluble in water at physiological pH, better absorbed and slowly transformed into levodopa in vivo; it consequently improves the duration of action and prevents the rapid fluctuations in response or involontary movements (dyskinesia) observed during chronic treatment with levodopa. In patients with a delayed effect of levodopa (on-phenomenon) or a severe resistance to L-Dopa (off-phenomenon), CHF- 1301 significantly improves the onset and the stability of the'response.

• Originator

  Chiesi Farmaceutici SpA (Italy)

• 상표명

  Levomet

(S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER 준비 용품 및 원자재

(S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER 공급 업체

Global(18)Suppliers